Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CICRVax6 in patients with persistent or recurrent genital warts
ACTRN12605000674639Phase 2Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CICRVax6 in anogenital warts (4 arms), sponsored by The University of Queensland. Primary endpoint: Percentage of patients disease free. Planned start Nov 2005; status: not yet recruiting.
02
Drugs
CICRVax6
03
Conditions
anogenital warts
Beyond the preview
Go deeper on ACTRN12605000674639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000674639.